Innomab Completes Angel+ Financing Led by Ouryao Healthcare Venture to Advance Proteomics-Driven AI Drug Discovery Platform and Next-Gen Bispecific ADC Pipeline

VCBeat recently learned that Innovmab Therapeutics (Shanghai) Co., Ltd. ("Innovmab Therapeutics") has completed an angel+ round of financing from Dandelion (Shenzhen) Pharmaceutical Venture Capital Co., Ltd. The funds will be used to deeply integrate proteomics technology platforms with drug development, creating multiple ADC pipelines with best-in-class potential.

Innovmab Therapeutics is a company driven by omics big data to develop targeted drugs and novel precision medical decision-making tools. Based on proteomics technology and various highly clinically relevant disease model libraries, including PDX/PDO, the company has established a distinctive drug R&D decision-making tool platform. By leveraging highly clinically relevant big data and deep biological insights obtained through AI computation, Innovmab accelerates the high-success-rate development of its proprietary new drug pipeline and IVD products. This technological platform provides rational decision-making data support for multiple key stages of new drug development, including target discovery, drug mechanism of action, patient selection, clinical trial design, determination of interim/surrogate endpoints in clinical studies, combination therapy development, clinical medication decision support, and drug indication expansion.

In terms of drug research and development, the company currently ownsMultiple innovative preclinical ADC drug pipelines, including unique target products based on more than 10 years of academic accumulation, which can be developed into first-in-class products, giving the company a differentiated competitive advantage. Innovmab Therapeutics will...Organoid Multi-Omics PlatformSupport the efficient and high success rate development of this ADC drug, and synchronize the development of combination therapies based on this product. Combination therapy is one of the most important development directions for ADC drugs. Through combination therapy, the effective dose of ADC can be significantly reduced, side effects minimized, and the therapeutic window expanded.

This technology platform will also be applied to the development of precise diagnostic and therapeutic markers for diseases. Complex diseases such as cancer are often caused by multi-gene abnormalities and exhibit high heterogeneity, making biomarkers play a crucial role in medical decision-making. However, there is still a severe lack of clinically available precise biomarkers. Major reasons contributing to the difficulty in developing effective biomarkers include the lack of drug efficacy-related clinical models, insufficient systematic efficacy data support, and low result comparability due to the absence of standardized high-quality data. To address this significant unmet clinical need, Innovmab Therapeutics' organoid multi-omics platform uses AI algorithms to establish relationships between drug efficacy and multi-omics data, enabling the screening of more precise combinations of drug efficacy markers and providing clinicians with evidence for precise medication decisions. Its core LDT product under development can simultaneously detect the activity of eight drug efficacy-related protein factors, guiding the use of targeted drugs based on the HER signaling pathway, covering various indications including breast cancer, non-small cell lung cancer, colorectal cancer, gastric cancer, pancreatic cancer, ovarian cancer, and melanoma.This product can be developed into an IVD kit for multi-target detection of tumor pathology slides with a completely new concept.

In terms of technology output and cooperation, the company can leverage its organoid omics technology platform to provide a series of high-value R&D enabling services for medical testing institutions, pharmaceutical companies, and biotech enterprises. These include screening for clinical diagnostic markers, co-development of novel LDT and IVD products, optimal indication assessment, drug repositioning, and more. The company has already utilized its proteomics technology to offer technical services to multiple domestic and international enterprises and research institutions.Including collaborative research with Novartis Pharmaceuticals (USA) on two HER pathway-targeted drugs.. The relevant article will be published in an international core journal.

The company has been invited to join the top pharmaceutical industry incubator, ATAI Life Sciences' international innovation platform in Beijing. It is about to establish a branch in Dandelion (Shenzhen) Pharmaceutical Venture Capital Co., Ltd.’s incubator and has formed strategic partnerships with several well-known proteomics industry chain companies in China.

Dr. Yong Zheng, Founder and CEO of Innovmab TherapeuticsAs an overseas high-level talent and specially appointed expert in Beijing, his educational background includes a bachelor's degree from Lanzhou University, a master's degree from Peking Union Medical College, and a Ph.D. from the University of Alberta in Canada. He also completed his postdoctoral training at the University of Toronto.Studied under the world-renowned Canadian oncologist, Academician Tony Pawson.Formerly served as an assistant researcher at the LTRI Institute of Mount Sinai Hospital, and as a professor and doctoral supervisor at the National Center for Protein Science (Beijing).Published a landmark article on proteomics in the Nature magazine, receiving support from multiple research funds including the National Key R&D Program of China and the National Natural Science Foundation of China. Co-founder and Chief Scientist, Dr. De-Xian ZhengProfessor at the School of Basic Medicine, Peking Union Medical College, and expert receiving special allowance from the State Council. Education and work experience includeUndergraduate from Peking University, Ph.D. jointly trained by the U.S. NIH and China CMMS, postdoctoral fellow at the U.S. FDA, guest professor at Harvard Medical School, former dean of the Institute of Basic Medical Sciences at Peking Union Medical College, director and chairman of the Academic Committee of the State Key Laboratory of Experimental Hematology, vice president of the Chinese Society for Immunology, executive council member of the International Union of Immunological Societies, etc. Led multiple "863", "973", and National Major New Drug Creation Plan funds. Former chief scientist and R&D president of Yuan Bio. Successfully led the development of three new drug INDs, obtaining 15 patents approved both domestically and internationally.The company has a multidisciplinary core team. Members not only have backgrounds from top research institutions such as Harvard University, the University of Toronto, the Wharton School, Tsinghua University, Peking University, Peking Union Medical College, the National Center for Protein Science, and the Shanghai Institute of Materia Medica at the Chinese Academy of Sciences, but also possess executive experience from leading pharmaceutical companies like Pfizer, Takeda, Fosun Pharma, as well as renowned tech companies such as Apple, Tencent Healthcare, and Alibaba Health. The company has world-class capabilities in the fields of proteomics, antibody drugs, and AI computing.

Founder and CEO of Innovmab Therapeutics, Zheng YongRepresentation: Innovating the healthcare and pharmaceutical R&D model through proteomics technology is an emerging international trend. Several cutting-edge companies overseas have garnered significant attention and support from investors, showing development progress that exceeds expectations. Compared to our对标企业, although we started slightly later, we possess unique technological advantages, including the latest generation of ADC pipeline technology, world-class proteomics expertise, and a distinctive organoid model library. I firmly believe that our new drug pipeline + clinical diagnostic tools + clinical omics big data + AI computing model represents the optimal path to achieving AI-driven drug discovery. Special thanks go to Dandelion (Shenzhen) Pharmaceutical Venture Capital Co., Ltd. and Mr. Zhang for their trust and support! Mr. Zhang’s extensive resources and hands-on experience in the pharmaceutical industry, coupled with the efficient and pragmatic work style of the entire Dandelion team, will provide crucial guidance and assistance for the business growth and commercialization of Innovmab Therapeutics.

Founder and Chairman of Dandelion (Shenzhen) Pharmaceutical Venture Capital Co., Ltd., Zhang JinweiRepresentation: The complex network of proteins and their compositions are the ultimate executors of life activities. Therefore, protein-related information measured by proteomics is directly associated with disease states. The tremendous potential of proteomics has started to gain recognition from capital, and Innovmab Therapeutics possesses proteomics technology of international first-class standards as well as a unique organoid model library. Its pipeline of new drugs + clinical testing tools + clinical omics big data + AI computing model represents an ideal path for realizing AI-driven drug discovery and precision medicine.

As a leading technology service platform in China's pharmaceutical industry ecosystem, it has more than 1.2 million vertical professional users in the biopharmaceutical industry and has built pharmaceutical service co-creation platforms with a total area of over 8,000 square meters in Beijing, Shanghai, Guangzhou, Shenzhen, Suzhou, Chengdu, Tianjin, and Toronto. It has formed ten major sectors: "venture capital, education, media, products, parks, consulting, talent, forums, mall, and alliance," serving the ecological cluster of the pharmaceutical industry.

Focusing on angel investments in the biopharmaceutical field, I am very pleased to have the opportunity to become a part of Innovmab Therapeutics. I am willing to be a long-term companion to Innovmab Therapeutics and leverage all resources from Dandelion (Shenzhen) Pharmaceutical Venture Capital Co., Ltd. to empower the development of Innovmab Therapeutics. Through mutual collaboration, we aim to achieve significant synergy. We are confident in becoming a leading enterprise in the new generation of AI-driven pharmaceuticals through multi-omics approaches.